Expression and cell type--specific processing of human preproenkephalin with a vaccinia recombinant.

The posttranslational maturation of a complex precursor polyprotein, human proenkephalin, was assessed by infection of a wide spectrum of cell types with a recombinant vaccinia virus that expressed human proenkephalin. The infected cells rapidly produced both cellular and secreted Met-enkephalin immunoreactivity. Although each cell line could secrete intact proenkephalin, only a mouse pituitary line was capable of processing proenkephalin to mature enkephalin peptides. The quantity of intact proenkephalin secreted from BSC-40 cells (derived from African Green monkey kidney) was sufficient to establish the value of vaccinia virus as a mammalian cell expression vector.

Protection against streptococcal pharyngeal colonization with a vaccinia: M protein recombinant.

Phagocytosis of group A streptococci requires type-specific antibodies directed against the variable determinants of the bacterial surface M protein molecule. As a step toward developing a broadly protective anti-streptococcal vaccine, a vaccinia virus (VV) recombinant was constructed that expresses the conserved region of the structural gene encoding the M6 molecule (VV:M6'). Mice immunized intranasally with the VV:M6' virus showed markedly reduced pharyngeal colonization by streptococci after intranasal and oral challenge with these bacteria. M protein-specific serum immunoglobulin G was significantly elevated in vaccinated animals and absent in controls. A similar approach may prove useful for the identification of protective determinants present on other bacterial and viral pathogens.

Yeast KEX2 endopeptidase correctly cleaves a neuroendocrine prohormone in mammalian cells.

Mammalian cell lines (BSC-40, NG108-15, and GH4C1) that cannot process the murine neuroendocrine peptide precursor prepro-opiomelanocortin (mPOMC) when its synthesis is directed by a vaccinia virus vector were coinfected with a second recombinant vaccinia virus carrying the yeast KEX2 gene, which encodes an endopeptidase that cleaves at pairs of basic amino acid residues. mPOMC was cleaved intracellularly to a set of product peptides normally found in vivo, including mature gamma-lipotropin and beta-endorphin1-31. In GH4C1 cells (a rat pituitary line), product peptides were incorporated into stored secretory granules. These results suggest that the inability of any particular cell line to process a prohormone precursor is due to the absence of a suitable endogenous processing enzyme.

Neomycin resistance as a dominant selectable marker for selection and isolation of vaccinia virus recombinants.

The antibiotic G418 was shown to be an effective inhibitor of vaccinia virus replication when an appropriate concentration of it was added to cell monolayers 48 h before infection. Genetic engineering techniques were used in concert with DNA transfection protocols to construct vaccinia virus recombinants containing the neomycin resistance gene (neo) from transposon Tn5. These recombinants contained the neo gene linked in either the correct or incorrect orientation relative to the vaccinia virus 7.5-kilodalton gene promoter which is expressed constitutively throughout the course of infection. The vaccinia virus recombinant containing the chimeric neo gene in the proper orientation was able to grow and form plaques in the presence of G418, whereas both the wild-type and the recombinant virus with the neo gene in the opposite polarity were inhibited by more than 98%. The effect of G418 on virus growth may be mediated at least in part by selective inhibition of the synthesis of a subset of late viral proteins. These results are discussed with reference to using this system, the conferral of resistance to G418 with neo as a positive selectable marker, to facilitate constructing vaccinia virus recombinants which contain foreign genes of interest.

Processing and secretion of nerve growth factor: expression in mammalian cells with a vaccinia virus vector.

To study posttranslational mechanisms for the control of nerve growth factor (NGF), we used a recombinant vaccinia virus vector to independently express the two major NGF transcripts in a variety of mammalian cell lines. The two major transcripts contain NGF (12.5 kilodaltons [kDa]) at the C-terminus and differ by alternative splicing of an N-terminal exon, so that the large precursor (34 kDa) had 67 amino acids upstream of an internal signal peptide and the smaller precursor (27 kDa) had this signal peptide at its N-terminus. In L929 cells, expression of either NGF transcript with the vaccinia virus vector gave rise to an apparently identical intracellular 35-kDa glycosylated precursor formed by cleavage of the primary gene product after the signal peptide. These cells also secreted biologically active NGF. To determine whether NGF processing is restricted by cell type, we infected a variety of mammalian cell lines with both recombinant viruses; all accumulated the same 35-kDa precursor and secreted NGF. Thus, many types of cells have the machinery to process and secrete NGF. However, NGF accumulated intracellularly (presumably in secretory granules) in cells with a regulated pathway of secretion (e.g., AtT-20 and HIT cells). In these cells, a membrane-permeable cyclic AMP analog, 8-bromo-cyclic AMP, stimulated NGF secretion. This suggests a mechanism for the regulation of NGF levels in which specific secretagogues, e.g., neurotransmitters, control NGF secretion.

Viral acylproteins: greasing the wheels of assembly.

Viruses take advantage of the host's protein modification and targeting pathways to modify their own proteins and to ensure that they assume active configurations and locate appropriately for assembly. In many viruses, one recurrent theme in such processes is exploitation of cellular protein acylation pathways for the addition of myristic and palmitic acid to capsid or envelope proteins.

Further characterization of an adenosine-containing modification of vaccinia virus proteins.

Three vaccinia virus (VV) core proteins which become labeled when virus is grown in the presence of radiolabeled adenosine or orthophosphate were identified as the major viral core proteins 4A, 4B, and 25K on the basis of comigration with [35S]methionine-labeled viral proteins and immunoprecipitation with monospecific polyclonal antisera. Boronate affinity chromatography and HPLC analysis suggested that a cis-diol-containing adenosine compound is present on this set of viral proteins. The replication of VV in tissue culture cells was prevented by the ADP-ribosylation inhibitors nicotinamide (NIC), 3-aminobenzamide (3-AB), and meta-iodobenzylguanidine (MIBG). None of these compounds significantly affected viral DNA synthesis at lower drug concentrations, although at higher concentrations of the three drugs a reduction in viral DNA synthesis was evident. Total VV protein synthesis also decreased at higher inhibitor levels, and the proteolytic processing of the major virion core proteins was greatly diminished as well. The three inhibitors also affected labeling of viral core proteins and cellular histone proteins by [8-14C]adenosine. In addition, mature, infectious virus particles were not formed in the presence of either 60 mM NIC or 3-AB, or 0.6 mM MIBG. These results provide evidence that the major VV core proteins are subject to modification by an adenosine compound, and suggest the possibility that this modification might represent ADP-ribosylation.

An ATP-dependent inhibition of protein synthesis in ascites cell extracts by wheat germ protein.

A high speed supernatant fraction from wheat germ was shown to be a very effective inhibitor of protein synthesis in a cell-free protein synthesizing system from Ehrlich ascites cells. Low concentrations of the extract were equally effective in inhibiting the translation of EMC viral RNA, ascites cell mRNA (exogenous) and endogenous mRNA. The kinetics of inhibition in the presence and absence of pactamycin, as well as the observed inhibition of polyphenylalanine synthesis, indicate that the wheat germ inhibitor acts at the level of elongation. Preincubation of the ascites system with the wheat germ inhibitor in the presence and absence of ATP showed that ATP was required for the development of the inhibition. The inhibitor was partially purified and appears to be a basic protein with a molecular weight of 30 000--40 000. These results are discussed with respect to the hypothesis that this may be another example of a protein kinase-induced inhibition of protein synthesis.

Isolation and characterization of mRNA from Paramecium aurelia.

Total cellular RNA was isolated from the ciliate protozoan Paramecium aurelia by pH 9.5 chloroform/octanol extraction. Passage of this RNA through an oligo(dT)-cellulose column in 0.5 M NaCl resulted in 2--3% binding, indicating the presence of polyadenylic acid sequences. These polyadenylic acid regions were estimated to be 250-500 nucleotides in length, based on their resistance to ribonuclease degradation. The oligo(dT)-cellulose bound RNA sedimented at 14--25 S in sodium dodecyl sulphate/sucrose gradients. The base composition of this RNA is similar to the base composition of the DNA. This RNA was also actively translated into protein by an in vitro protein synthesizing system isolated from wheat germ. Translation was optimal under conditions similar to those used for mammalian mRNA translation. In addition, translation of the P. aurelia oligo(dT)-cellulose bound RNA was inhibited 80% by the analog 7-methylguanosine-5'-phosphate, suggesting the presence of a 5'-capped terminus.

Uses of vaccinia virus in vaccine delivery.

The construction of vaccinia-based vaccines has been hampered by a lack of information on both the mechanisms of vaccinia-induced immunity in humans and the effect of prior exposure to vaccinia on the course of an immune response to a non-vaccinia antigen. Recent studies have investigated the immune responses induced by this virus in humans and the ability of recombinant viruses to successfully induce immunity to diverse pathogens with diverse routes of infection. In addition to the previously described ability of vaccinia to induce immune responses in experimental animals, the virus has been shown to encode modulators of immune function that may, in the future, permit the use of virus to induce qualitatively different immune responses to particular heterologous antigens.

Vaccinia virus: a versatile tool for molecular biologists.

Continued advances in genetic engineering have made possible the high-level expression of correctly processed cellular, viral and bacterial polypeptides. This article focuses on viral expression vectors and, more specifically, the vaccinia virus expression system. Vaccinia virus has been used to express a variety of proteins with useful immunogenic, catalytic or pharmaceutical properties. We discuss briefly the biology of vaccinia and its significance in the use of vaccinia as an expression vector, the variety of vaccinia systems currently in use and, finally, we summarize some recent developments which bode well for future applications of vaccinia virus technology.

Vaccinia virus: a novel approach for molecular engineering of peptide vaccines.

One of the more promising new approaches for producing prophylactic vaccines involves the genetic engineering of vaccinia virus (VV) strains to express a single protein, a portion of a protein, or a single epitope from a heterologous pathogen. As an example, the application of this approach to the prevention of streptococcal-related diseases is considered. Experiments are described in which several generations of VV-based recombinant vaccines were constructed that expressed various derivatives of the M protein gene from Streptococcus pyogenes (serotype 6). These recombinants were used to demonstrate the high-level expression, stability, and antigen authenticity of the bacterial proteins expressed in infected tissue culture cells. When tested in a mouse model system, immunization with the VV recombinants expressing specific subdomains of the M protein conferred protection to challenge from both homologous and heterologous serotypes of pathogenic streptococci.

Construction of recombinant vaccinia virus strains using single-stranded DNA insertion vectors.

The ability of single-stranded (ss) DNA, isolated from recombinant M13 bacteriophage, to direct the insertion of foreign genetic elements into the vaccinia virus (VV) genome was examined. An identical chimeric transcriptional unit [VV promoter/chloramphenicol acetyl transferase (CAT) gene embedded in DNA sequences encoding vaccinia virus thymidine kinase (TK)] was inserted into either the previously characterized plasmid insertion vector, pGS20, or into M13mp18. It was found that the ss vector (M13mp18:TK/CAT) was four times more efficient than the plasmid vector (pGS20:CAT) in catalyzing homologous recombination of the cat gene by marker transfer into the VV genome. Furthermore, Southern blot analyses and CAT enzymatic activity assays confirmed that the structure of the M13-derived recombinant genomes were as expected and that the chimeric genes were fully active. Although the precise mechanism responsible for the ss DNA-catalyzed insertion event is not known, these results are discussed with respect to the advantages of using M13-based vectors with which to manipulate and insert genetic information into infectious VV recombinants.

Expression vector pT7:TKII for the synthesis of authentic biologically active RNA encoding vaccinia virus thymidine kinase.

A transcription vector, pT7: TKII, was constructed by a novel application of the polymerase chain reaction. Chimeric oligodeoxynucleotides were used to direct the synthesis of a DNA fragment which consisted of a truncated bacteriophage T7 promoter element fused to the vaccinia virus (VV) thymidine kinase gene (tk). This fragment was cloned into a pUC118 plasmid and sequenced to ensure no mutations had occurred during its synthesis. When linearized at the 3' end of the VV tk gene at the BamHI site located in the polylinker region of the vector, pT7:TKII was efficiently transcribed by T7 RNA polymerase into a 595 nucleotide transcript whose 5' end was identical to that found on authentic nascent VV tk mRNA. When translated in a rabbit reticulocyte lysate system, the synthetic VV tk RNA was shown to be biologically active in that it directed the synthesis of a 20-kDa protein which assembled into an enzymatically active 80-kDa tetrameric complex which was indistinguishable from VV thymidine kinase (TK) enzyme isolated from VV-infected cells. The pT7:TKII vector provides a powerful approach with which: (i) to investigate the translational and posttranslational regulation of the VV tk gene; (ii) to use directed genetics to identify potential cis-acting regulatory sequences or structures present within the VV tk RNA; and (iii) to apply protein engineering procedures to identify the catalytic, allosteric and subunit interactive domains of the VV TK enzyme. As an example, the translational effects of adding a m7G cap structure to the pT7:TKII-derived VV tk RNA are presented.

Biology of vaccinia virus acylproteins.

Posttranslational processing of vaccinia virus proteins has proven to be a common mechanism for exerting regulatory control of function or targeting to subcellular and/or subviral structures. Fatty acylation, most commonly observed as the addition of myristate or palmitate, occurs on numerous vaccinia proteins and affects each in a distinct manner. Labeling of vaccinia-infected cells with tritiated myristic or palmitic acids demonstrates that vaccinia encodes at least six myristylproteins and six palmitylproteins. Where investigated, each of these proteins have been demonstrated to play important roles in the virus life cycle. Likewise, in each case studied, the fatty acyl modification greatly influences the function and/or biological activity of the protein.

Inhibition of vaccinia virus thymidine kinase by the distal products of its own metabolic pathway.

Vaccinia virus thymidine kinase activity is inhibited by low concentrations (10 microM) of dTDP or dTTP, but not by dTMP. This inhibition is specified for the thymidine nucleotides as dATP, dGTP, and dCTP have no effect. The viral enzyme phosphorylates thymidine to dTMP with typical first-order kinetics. However, evidence was obtained to indicate that the observed dTTP inhibition was noncompetitive in nature. This suggests that thymidine and dTTP interact with different sites in the native viral enzyme.

Novel codon utilization within the vaccinia virus thymidine kinase gene.

The nucleotide and predicted amino acid sequences of the thymidine kinase genes encoded by vaccinia virus and herpes simplex virus (type 1) were analyzed, and there was no evidence of any significant homology. The manner in which the triplet code was used by each virus was also examined. The frequencies of codon utilization by the herpes virus gene were very similar to those used by most human genes, whereas the vaccinia virus gene was quite distinct, suggesting novel evolutionary and regulatory mechanisms.

Inhibition of vaccinia virus replication by nicotinamide: evidence for ADP-ribosylation of viral proteins.

Replication of vaccinia virus (VV) in monolayers of BSC40 cells was inhibited 99.9% in the presence of 60 mM nicotinamide (NIC), a competitive inhibitor of ADP-ribosylation reactions. Dot-blot hybridization analysis of infected cell extracts utilizing a VV DNA-specific probe indicated that the drug had only minimal effects on viral DNA synthesis. SDS-polyacrylamide gel electrophoresis of newly synthesized VV proteins pulse-labeled at early (2 h) or late (8 h) times post-infection revealed that although the full spectrum of expected viral polypeptides was evident, quantitative differences in the levels of expression of a distinct subset of viral proteins were observed in the presence of the drug. Velocity sedimentation of virus-infected cell lysates established that no mature particles were assembled in drug treated cells. Additional evidence suggesting that VV morphogenesis was abortive in the presence of NIC was obtained by pulse-chase labeling experiments that demonstrated that the two VV major late core polypeptide precursors P94 and P65, whose proteolytic processing to VP62 and VP60 is intimately associated with viral assembly, were not cleaved in the presence of NIC. Interestingly, growth of VV in the presence of [3H]adenosine resulted in the metabolic labeling of eight proteins that were associated with purified virions. These proteins co-migrated with proteins labeled with [3H]adenosine that were present in extracts of VV-infected, but not uninfected, cells. These analyses also revealed that the [3H]adenosine-labeling of a subset of cellular proteins (MW 18-20 kDa, possibly histones) was increased 4-fold by VV infection. The observed induction of either increased synthesis or hyper-modification of these 18-20 kDa proteins was inhibited by NIC. These results are discussed with respect to whether one or more VV polypeptides are subject to obligatory ADP-ribosylation modification reactions in order to attain their active configuration, and if so, whether the enzymes catalyzing these reactions are specified by the virus or host cell.

Expression and regulation of the vaccinia virus thymidine kinase gene in non-permissive cells.

The expression and regulation of the vaccinia virus (VV) thymidine kinase (tk) gene was examined in two non-permissive cell lines, CHO and MDBK, which restrict VV development at different stages of the viral replication cycle. The VV tk gene was expressed in these two cell lines with kinetics similar to a fully permissive cell line BSC40. These results are consistent with the hypothesis that inhibition of tk mRNA translation by another viral early gene product is a normal component of the overall strategy employed to express and regulate the VV tk gene during a productive infection.

Novel acylation of poxvirus A-type inclusion proteins.

Myristylation is one of several post-translational modifications that occur on vaccinia virus (VV) proteins. Previously, time course labeling of VV-infected cells with myristic acid had indicated that five late proteins (17, 25, 36, 38 and 92 kDa) are myristylated. Four of these proteins were mapped to the E7R, L1R, AI6L and G9R open-reading frames, respectively, because of the predicted presence of the N-myristyltransferase recognition sequence (M-G-X-X-X-S/T/A) at their amino termini. In contrast, computer analyses of large (80-100 kDa) VV open reading frames did not reveal any predicted species with this N-terminal motif. By immunoprecipitation with monospecific sera and transient expression of cloned gene products, the myristylated 92-kDa protein has been demonstrated to be the A-type inclusion protein encoded by the Western Reserve (WR) strain of VV. Labeling of cowpox virus (CPV) infected cells with myristic acid indicated that the 160-kDa A-type inclusion protein appears to be myristylated as well. Both the VV 92-kDa and the CPV 160-kDa A-type inclusion proteins labeled with myristic acid were stable to hydroxylamine treatment, suggesting an amide linkage between the fatty acid and the acceptor protein. HPLC analysis confirmed that the 92-kDa protein was in fact myristylated. This data suggests that poxvirus ATI proteins may be subject to a novel type of internal myristylation modification, and the roles such modifications may play in the replication cycles of these viruses is discussed.